CoronaryAtlas logo
CoronaryAtlas
Myoglobin
Pathway / Myocardial injury (shared endpoint)

Myoglobin

MBprotein

Myoglobin released from ischemic cardiomyocytes serves as an early biomarker of myocardial infarction and necrotic injury.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleEarly marker of myocardial necrosis and ischemic injury; cardiomyocyte damage product.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000198125

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — non-Type-I
47
A — assay feasibility
96
E — evidence strength
31
T1DI (composite)
10
Specificity differential (R−C)-31.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 0
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuremag 2
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 5/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 10 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Immunoturbidimetric or immunoassay
Reagent / substrate
Anti-myoglobin antibody-coated latex particles
Platform
Automated analyzer
Turnaround · availability
STAT–routine · FDA-cleared

Human genetic evidence

0.003
Open Targets association (NSTEMI)

Literature evidence(14)